Linda M. Chatwin, Esq. RAC Business Manager, UL LLC

Slides:



Advertisements
Similar presentations
Regulatory Pathway for Platform Technologies
Advertisements

Overview of FDA Device Regulations
"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
Strengthening the Medical Device Clinical Trial Enterprise
Development of Guidance Documents Jennifer Scharpf, M. P. H
510k Submission Overview Myraqa, Inc. August 22, 2012.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.
Conversation on the Chemical Facility Anti-Terrorism Standards (CFATS) and Critical Infrastructure Protection Chemical-Terrorism Vulnerability Information.
Medical Device User Fee Reauthorization & FDA Update Roadmap to a Successful 510(K) Submission For Your Medical Device August 22, 2012.
Introduction to Regulation
Medical Devices Approval Process
Cross-Labeling: Legal and Regulatory Issues David M. Fox Hogan & Hartson LLP th Street, NW Washington, DC
CBER Managed Review Process Sheryl A. Kochman Deputy Director, DBA, OBRR, CBER September 15, 2009.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
FDA Resources and Meetings FDA/EMA Orphan Designation and Grant Workshop Silver Spring, Maryland FDA Campus (White Oak) October 12, 2012 Bill Sutton Deputy.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Regulatory Overview.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)
Legal Issues Impacting Clinical Trials Medical Device Clinical Trials Update June 19, 2009.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Staffing and Training.
OIVD Workshop Premarket Notification (510(k)) April 22, 2003 Parklawn Building Rockville, MD Presented by Marjorie Shulman Premarket Notification Staff.
FDA Focus On Consumer Protection
March 28, 2006 Combination Products: Preparing for the Journey March 28, 2006 Pamela J. Weagraff Principal Consultant.
Latham & Watkins operates as a limited liability partnership worldwide with affiliated limited liability partnerships conducting the practice in the United.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
“513(g)s” Requests for Information Lawrence “Jake” Romanell, RM (AAM) Office of Device Evaluation Center for Devices and Radiological Health.
1 Combination Products: Jurisdictional Issues MassMEDIC Presentation March 28, 2006 Janice Hogan, Esq. Partner Hogan & Hartson, LLP
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
Rules for Supporting Part 803 and Part 806 Decision Making Page 1 Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports.
REGULATION OF COMBINATION PRODUCTS Mark A. Heller Wilmer Cutler Pickering Hale and Dorr LLP MassMEDIC Combination Product Program, March 28, 2006.
FDAAA – Report on DTC Advertising Kristin Davis, J.D. Deputy Director, Division of Drug Marketing, Advertising, and Communications Office of Medical Policy,
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Investigational Devices and Humanitarian Use Devices June 2007.
FDA ICH Public Meeting 5630 Fishers Lane, Rockville, MD May 8, :30 am -- 2:00 pm Implementation of the CTD Update-Issues-Next Steps Justina A. Molzon,
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
AMERICAS | ASIA PACIFIC | EMEA Medical Devices: Concept to Commercialization How to avoid delays in getting your product cleared/approved by FDA Robert.
Device regulations USA Dr Phil Warner. USA Regulations MEDICAL DEVICES Food, Drug & Cosmetics Act Medical Device Amendments of 1976 (and other things)
FSMA TRAINING Industry Recall Readiness BEST PRACTICES.
Medical Device Software Development
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
DOL Employee Benefit Plan Audits & How to Prepare
FDA's Two New Draft Guidance on Software and Device
ClinicalTrials.gov Requirements
Conditional IRB Approval
Pat Nestor MSCSI MRICS Head of Building Control Dublin City Council
Division of Cardiovascular Devices
U.S. FDA Center for Devices and Radiological Health Update
Premarket Notification 510(k) process
FDA’s IDE Decisions and Communications
How to Put Together an IDE Application
The Current PMA Requirements
Medical Device Premarket Submission Challenges and the Effect of MDUFA IV Robin Fatzinger, RAC VP, Regulatory Affairs Aesculap
Biotechnology Chemical Pharmaceutical Customer Partnership
Standards and Certification Training
The Federal Insurance Office & Dodd-Frank
Michael Gross, Ph.D., RAC Vice-President Worldwide Compliance
FDA Resources and Meetings
EEO MODULE 3: DISCRIMINATION COMPLAINT PROCESSING
Managing Federal grants
Opening an IND: Investigator Perspective
The Office of Open Records webinar will begin soon
Regulatory Perspective of the Use of EHRs in RCTs
System Safety Regulation
FDA Regulation of Animal Biotechnology Products
Presentation transcript:

Linda M. Chatwin, Esq. RAC Business Manager, UL LLC FDA’s 513(g) What is it? Linda M. Chatwin, Esq. RAC Business Manager, UL LLC

Areas of regulatory expertise: Developing international regulatory strategy US FDA 510(k) and other regulatory submissions Remediation efforts from audit findings Quality system construction and improvement Training to QSR, Risk management, RoHS and safety standards Risk management file construction and maintenance Gap assessments to various certification standards 21 CFR Part 11 implementation Performing FDA Mock Audit and other outside auditing Managing FDA inspections Developing, implementing and mitigating design control processes

Agenda Guidance User Fees Specifics Who we are Q&A

Guidance

http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm209851.pdf

Request for information about the class of a device What is a 513(g)   Request for information about the class of a device Request for the requirements that apply Caveat: Guidance does not establish legally enforceable responsibilities Describe the Agency's current thinking Recommendations, unless specific regulatory or statutory requirements are cited

User Fees Guidance for Industry and Food and Drug Administration Staff - User Fees for 513(g) Requests for Information http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm209852.htm Title II of the Food and Drug Administration Amendments Act of 2007 (FDAAA), also termed the Medical Device User Fee Amendments of 2007, P.L. 110-85, extends FDA’s authority to collect medical device user fees by establishing a fee for “a request for classification information.” 

Q&A Regarding 513(g) User Fees  Are all 513(g) requests subject to a user fee? Yes Will FDA refund my user fee payment if you determine that my submission is not a 513(g) Request for Information?  Will FDA refund my user fee payment if my product does not appear to be a medical device? No Will FDA refund my user fee payment if my device appears to be exempt from 510(k) premarket notification?

Continued After I submit a 513(g) Request for Information, can I subsequently add a new question, use, or technology without submitting a new user fee? No Will FDA refund my user fee payment if I withdraw my 513(g) request? Current 2016 User fees for 513(g) requests Regular: $3,529; Small Business: $1,765

Specifics

Forward Obtain the agency's views about classification Applicable requirements Within sixty days…, the Secretary shall provide a written statement of the classification (if any) and the requirements applicable to the device.”

What if it Isn’t? Governs requests for information about the classification or requirements Submissions that do not request such information are outside the scope If, based solely on the information provided with the request, the product doesn’t appear to be a "device", FDA will inform the requester

What does the Request Provide? The agency's assessment, based on the information submitted in the request, as to the generic type of device (e.g., classification regulation) that the requester's device appears to be within (if any); The class of devices within that generic type (and if there is more than one class within that generic type, the particular class within which the requestor's device appears to fall) Whether a PMA, 510(k), or neither is required in order to market devices of the particular class within that generic type

Continued Other requirements applicable to devices of the particular class within that generic type Whether a guidance document has been issued regarding the exercise of enforcement discretion over the particular class of devices within that generic type Whether additional FDA requirements may apply, such as those applicable to radiation-emitting products.

Equivalency? Safety? Effectiveness? FDA does not review data related to substantial equivalence FDA does not review safety and effectiveness FDA's responses are not device classification decisions Do not constitute FDA clearance or approval for marketing.

Studies? FDA’s response will not address the specific types of nonclinical, animal, or clinical studies Consider a Pre-Sub to receive more specific information about your specific testing recommendation

What’s Included in the Request? a cover letter a description of the device a description of what the device is to be used for any proposed labeling or promotional material for the device labeling or promotional material of a similar, legally marketed device

What if it isn’t a Device? May be another type of product regulated by FDA Contact information for another department Appears not to be a product for which FDA has jurisdiction Combination product where it is not clear which Center has primary jurisdiction. Contact the Office of Combination Products.

FDA is unable to provide information: Incomplete Request FDA is unable to provide information: If your 513(g) Request for Information is incomplete Or insufficient information is submitted FDA intends to contact the submitter and request additional information May consider request withdraw if no response within 30 days Issue notice of withdrawal

Issues FDA’s assessment is not binding and there are no appeal rights Can argue against FDA’s response in future premarket submission However, FDA may maintain position consistent with response FDA will not provide information on substantial equivalence or predicates

UL NOW OFFERS – Full Support During Product Life Cycle

Summary 513(g) a tool to help with classification concerns Must be thorough; ask specific questions Will not bind FDA Will not provide studies information Will not provide SE information May need to file Pre-Sub

Questions? Linda M. Chatwin, Esq. RAC Business Manager, UL LLC Email: linda.chatwin@ul.com Phone: 360-817-5556